Atara Biotherapeutics ATRA Stock
Atara Biotherapeutics Price Chart
Atara Biotherapeutics ATRA Financial and Trading Overview
| Atara Biotherapeutics stock price | 11.16 USD |
| Previous Close | 10.07 USD |
| Open | 9.93 USD |
| Bid | 7.56 USD x 200 |
| Ask | 12.88 USD x 200 |
| Day's Range | 9.66 - 10.71 USD |
| 52 Week Range | 3.92 - 19.15 USD |
| Volume | 95.14K USD |
| Avg. Volume | 1.42M USD |
| Market Cap | 95.6M USD |
| Beta (5Y Monthly) | 0.108 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.22 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.67 USD |
ATRA Valuation Measures
| Enterprise Value | 97.33M USD |
| Trailing P/E | N/A |
| Forward P/E | 8.354331 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4.131463 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 4.206 |
| Enterprise Value/EBITDA | -44.997 |
Trading Information
Atara Biotherapeutics Stock Price History
| Beta (5Y Monthly) | 0.108 |
| 52-Week Change | 31.63% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 19.15 USD |
| 52 Week Low | 3.92 USD |
| 50-Day Moving Average | 8 USD |
| 200-Day Moving Average | 9.99 USD |
ATRA Share Statistics
| Avg. Volume (3 month) | 1.42M USD |
| Avg. Daily Volume (10-Days) | 94.3K USD |
| Shares Outstanding | 9.01M |
| Float | 4.66M |
| Short Ratio | 0.12 |
| % Held by Insiders | 16.92% |
| % Held by Institutions | 52.45% |
| Shares Short | 484.39K |
| Short % of Float | 7.66% |
| Short % of Shares Outstanding | 5.37% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:25 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -40.91% |
| Operating Margin (ttm) | -652.90% |
| Gross Margin | 70.11% |
| EBITDA Margin | -9.34% |
Management Effectiveness
| Return on Assets (ttm) | -3.82% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 23.14M USD |
| Revenue Per Share (ttm) | 1.73 USD |
| Quarterly Revenue Growth (yoy) | -99.50% |
| Gross Profit (ttm) | 16.22M USD |
| EBITDA | -2163000 USD |
| Net Income Avi to Common (ttm) | -9467000 USD |
| Diluted EPS (ttm) | -1.22 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 8.36M USD |
| Total Cash Per Share (mrq) | 0.93 USD |
| Total Debt (mrq) | 10.09M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 2.156 |
| Book Value Per Share (mrq) | -4.383 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -25875000 USD |
| Levered Free Cash Flow (ttm) | -16998750 USD |
Profile of Atara Biotherapeutics
| Country | United States |
| State | CA |
| City | Thousand Oaks |
| Address | 1280 Rancho Conejo Blvd |
| ZIP | 91320 |
| Phone | 805 623 4211 |
| Website | https://www.atarabio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 13 |
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Q&A For Atara Biotherapeutics Stock
What is a current ATRA stock price?
Atara Biotherapeutics ATRA stock price today per share is 11.16 USD.
How to purchase Atara Biotherapeutics stock?
You can buy ATRA shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Atara Biotherapeutics?
The stock symbol or ticker of Atara Biotherapeutics is ATRA.
Which industry does the Atara Biotherapeutics company belong to?
The Atara Biotherapeutics industry is Biotechnology.
How many shares does Atara Biotherapeutics have in circulation?
The max supply of Atara Biotherapeutics shares is 9.01M.
What is Atara Biotherapeutics Price to Earnings Ratio (PE Ratio)?
Atara Biotherapeutics PE Ratio is now.
What was Atara Biotherapeutics earnings per share over the trailing 12 months (TTM)?
Atara Biotherapeutics EPS is -1.22 USD over the trailing 12 months.
Which sector does the Atara Biotherapeutics company belong to?
The Atara Biotherapeutics sector is Healthcare.
Atara Biotherapeutics ATRA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
US Tech Composite Total Return
XCMP
US
|
31560.2 USD — |
-2.21
|
— — | 31469.2 USD — | 31924.72 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
|
US Tech Biotechnology Total Retu
XNBI
US
|
6750.7 USD — |
+0.85
|
— — | 6680.28 USD — | 6803.27 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
12546.99 USD — |
-2.24
|
— — | 12513.27 USD — | 12692.24 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6185.56 USD — |
+0.85
|
— — | 6121.03 USD — | 6233.73 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
- {{ link.label }} {{link}}